Marianna Mancini Biography and Net Worth



Marianne Mancini serves as our Chief Operating Officer. Ms. Mancini has more than 30 years of experience in the pharmaceutical and biotechnology industry focusing on the management and oversight of clinical trials from early-stage to late-stage drug development and most recently served as the company’s senior vice president of clinical operations. Prior to joining Viking, she was Senior Director of Clinical Operations at Ambit Biosciences Corporation, a company focused primarily on the development of oncology therapies for the treatment of Acute Myeloid Leukemia (AML). Previously, Ms. Mancini was the Senior Director of Clinical Operations at Aires Pharmaceuticals, Inc., a company focused on developing therapies for pulmonary vascular disorders. At Arena Pharmaceuticals, Inc, she served as Senior Director of Project Management and Clinical Operations and was also the Project Team Leader for the company’s lead obesity compound, BELVIQ®‎. Ms. Mancini held management positions at Baxter BioSciences a division of Baxter Healthcare Corporation where she was the Global Director of Clinical Operations overseeing the company’s global clinical trials involving coagulation disorders, biosurgery, and critical care. She has also previously held positions at Genentech and Procter & Gamble Pharmaceuticals. Ms. Mancini holds a MA in Bioethics from Loyola Marymount University, a MBA from the University of Phoenix, and a BS in Nutritional Sciences from McGill University.

What is Marianna Mancini's net worth?

The estimated net worth of Marianna Mancini is at least $15.30 million as of July 30th, 2024. Ms. Mancini owns 362,149 shares of Viking Therapeutics stock worth more than $15,300,795 as of December 21st. This net worth estimate does not reflect any other assets that Ms. Mancini may own. Learn More about Marianna Mancini's net worth.

How do I contact Marianna Mancini?

The corporate mailing address for Ms. Mancini and other Viking Therapeutics executives is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. Viking Therapeutics can also be reached via phone at (858) 704-4660 and via email at [email protected]. Learn More on Marianna Mancini's contact information.

Has Marianna Mancini been buying or selling shares of Viking Therapeutics?

Marianna Mancini has not been actively trading shares of Viking Therapeutics during the last ninety days. Most recently, Marianna Mancini sold 18,026 shares of the business's stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $57.13, for a transaction totalling $1,029,825.38. Following the completion of the sale, the chief operating officer now directly owns 362,149 shares of the company's stock, valued at $20,689,572.37. Learn More on Marianna Mancini's trading history.

Who are Viking Therapeutics' active insiders?

Viking Therapeutics' insider roster includes Matthew Foehr (Director), Brian Lian (CEO), Lawson Macartney (Director), Marianna Mancini (COO), Sarah Rouan (Director), Charles Rowland, Jr. (Director), J. Matthew Singleton (Director), and Greg Zante (CFO). Learn More on Viking Therapeutics' active insiders.

Are insiders buying or selling shares of Viking Therapeutics?

In the last year, insiders at the biotechnology company sold shares 19 times. They sold a total of 1,383,618 shares worth more than $81,779,033.02. The most recent insider tranaction occured on November, 8th when Director Lawson Macartney sold 2,000 shares worth more than $137,340.00. Insiders at Viking Therapeutics own 4.7% of the company. Learn More about insider trades at Viking Therapeutics.

Information on this page was last updated on 11/8/2024.

Marianna Mancini Insider Trading History at Viking Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/30/2024Sell18,026$57.13$1,029,825.38362,149View SEC Filing Icon  
5/1/2024Sell281,425$78.66$22,136,890.50348,508View SEC Filing Icon  
4/17/2023Sell12,500$20.00$250,000.00287,763View SEC Filing Icon  
3/29/2023Sell41,242$16.00$659,872.00261,895View SEC Filing Icon  
See Full Table

Marianna Mancini Buying and Selling Activity at Viking Therapeutics

This chart shows Marianna Mancini's buying and selling at Viking Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Viking Therapeutics Company Overview

Viking Therapeutics logo
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $42.25
Low: $41.97
High: $45.00

50 Day Range

MA: $58.05
Low: $38.28
High: $78.03

2 Week Range

Now: $42.25
Low: $17.23
High: $99.41

Volume

8,815,748 shs

Average Volume

4,483,956 shs

Market Capitalization

$4.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88